Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RTW Biotech Opportunities invests in innovative life science companies developing next-generation therapies. Recent clinical results from its portfolio include positive phase 1/2 data for TSHA-102 gene therapy in Rett syndrome by Taysha Gene Therapies, promising phase 2 data for Merus’s petosemtamab antibody in head and neck cancer, as well as ongoing pivotal trials at Rocket Pharmaceuticals for Danon disease[6][9]. The fund has also experienced setbacks such as a clinical hold on Rocket Pharma’s RP-A501 program following a patient death[6][9].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RTW Biotech Opportunities.